Difference between revisions of "Non-small cell lung cancer"
m (formatting of headers) |
m (alphabatized regimens, links to example orders) |
||
Line 6: | Line 6: | ||
=Adjuvant therapy= | =Adjuvant therapy= | ||
− | == | + | ==Carboplatin (Paraplatin) & Paclitaxel (Taxol)== |
− | ===Regimen | + | ===Regimen=== |
− | *[[ | + | *[[Carboplatin (Paraplatin)]] AUC 6 IV over 45-60 minutes day 1 |
− | *[[ | + | *[[Paclitaxel (Taxol)]] 200 mg/m2 IV over 3 hours day 1 |
+ | |||
+ | '''21-day cycles x 4 cycles''' | ||
+ | |||
+ | ===References=== | ||
+ | # Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 1;26(31):5043-51. Epub 2008 Sep 22. [http://jco.ascopubs.org/content/26/31/5043.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18809614 PubMed] | ||
− | + | ==Cisplatin (Platinol) & Docetaxel (Taxotere)== | |
− | ===Regimen | + | ===Regimen=== |
− | *[[Cisplatin (Platinol)]] 75 | + | *[[Cisplatin (Platinol)]] 75 mg/m2 IV day 1 |
− | *[[ | + | *[[Docetaxel (Taxotere)]] 75 mg/m2 IV day 1 |
'''21-day cycles x 4 cycles''' | '''21-day cycles x 4 cycles''' | ||
− | + | *[[Example orders for adjuvant Cisplatin (Platinol) and Docetaxel (Taxotere) in non-small cell lung cancer]] | |
− | *[[Cisplatin (Platinol) | ||
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
− | # | + | # Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003 Aug 15;21(16):3016-24. Epub 2003 Jul 1. [http://jco.ascopubs.org/content/21/16/3016.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12837811 PubMed] |
− | |||
− | |||
− | |||
==Cisplatin (Platinol) & Etoposide (Vepesid)== | ==Cisplatin (Platinol) & Etoposide (Vepesid)== | ||
Line 36: | Line 34: | ||
'''28-day cycles x 4 cycles''' | '''28-day cycles x 4 cycles''' | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
Line 63: | Line 47: | ||
===References=== | ===References=== | ||
# Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51. Epub 2008 May 27. [http://jco.ascopubs.org/content/26/21/3543.full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18506025 PubMed] | # Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51. Epub 2008 May 27. [http://jco.ascopubs.org/content/26/21/3543.full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18506025 PubMed] | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Cisplatin (Platinol) & Pemetrexed (Alimta)== | ==Cisplatin (Platinol) & Pemetrexed (Alimta)== | ||
Line 84: | Line 58: | ||
# Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51. Epub 2008 May 27. [http://jco.ascopubs.org/content/26/21/3543.full link to original article] '''contains protocol; note: reference was not for adjuvant therapy; patients in this study were stage IIIB or IV''' [http://www.ncbi.nlm.nih.gov/pubmed/18506025 PubMed] | # Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51. Epub 2008 May 27. [http://jco.ascopubs.org/content/26/21/3543.full link to original article] '''contains protocol; note: reference was not for adjuvant therapy; patients in this study were stage IIIB or IV''' [http://www.ncbi.nlm.nih.gov/pubmed/18506025 PubMed] | ||
− | == | + | ==Cisplatin (Platinol) & Vinblastine (Velban)== |
===Regimen=== | ===Regimen=== | ||
− | *[[ | + | *[[Cisplatin (Platinol)]] 80 mg/m2 IV on day 1 |
− | *[[ | + | *[[Vinblastine (Velban)]] 4 mg/m2 IV on days 1, 8, 15 of cycle 1 |
+ | :*[[Vinblastine (Velban)]] 4 mg/m2 IV on days 1 & 8 of cycle 2 | ||
+ | :*[[Vinblastine (Velban)]] 4 mg/m2 IV on days 1 & 15 of cycle 3 | ||
+ | :*[[Vinblastine (Velban)]] 4 mg/m2 IV on day 8 of cycle 4 | ||
+ | :Note: The above vinblastine schedule is based on it being given as described every 2 weeks after cycle 2 day 8 | ||
'''21-day cycles x 4 cycles''' | '''21-day cycles x 4 cycles''' | ||
===References=== | ===References=== | ||
− | # | + | # Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60. [http://www.nejm.org/doi/full/10.1056/NEJMoa031644 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/14736927 PubMed] |
− | + | ==Cisplatin (Platinol) & Vinorelbine (Navelbine)== | |
− | == | + | ===Regimen #1, Winton, et al. 2005=== |
− | ===Regimen=== | + | *[[Cisplatin (Platinol)]] 50 mg/m2 IV on days 1 & 8 |
− | *[[Cisplatin (Platinol)]] 50 mg/m2 IV on days 1 | + | *[[Vinorelbine (Navelbine)]] 25 mg/m2 IV on days 1, 8, 15, 22 |
− | *[[ | ||
− | |||
− | ''' | + | '''28-day cycles x 4 cycles''' |
+ | ===Regimen #2, Hotta, et al. 2001=== | ||
+ | *[[Cisplatin (Platinol)]] 75-80 mg/m2 IV on day 1 | ||
+ | *[[Vinorelbine (Navelbine)]] 25-30 mg/m2 IV on days 1, 8 | ||
− | + | '''21-day cycles x 4 cycles''' | |
− | === | + | ===Regimen #3, Arriagada, et al. 2004 & Douillard, et al. 2006=== |
− | # | + | *[[Cisplatin (Platinol)]] 100 mg/m2 IV on day 1 |
+ | *[[Vinorelbine (Navelbine)]] 30 mg/m2 IV on days 1, 8, 15, 22 | ||
− | + | '''28-day cycles x 4 cycles''' | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | ''' | ||
===References=== | ===References=== | ||
− | # | + | # Hotta K, Sekine I, Tamura T, Sawada M, Watanabe H, Kusaba H, Akiyama Y, Inoue A, Shimoyama T, Nokihara H, Ueda Y, Yamamoto N, Kunitoh H, Ohe Y, Kodama T, Saijo N. A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol. 2001 Dec;31(12):596-600. [http://jjco.oxfordjournals.org/content/31/12/596.full.pdf link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11902490 PubMed] |
+ | # Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60. [http://www.nejm.org/doi/full/10.1056/NEJMoa031644 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/14736927 PubMed] content property of HemOnc.org | ||
+ | # Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23;352(25):2589-97. [http://www.nejm.org/doi/full/10.1056/NEJMoa043623 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/15972865 PubMed] | ||
+ | # Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006 Sep;7(9):719-27. [http://linkinghub.elsevier.com/retrieve/pii/S1470-2045%2806%2970804-X link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/16945766 PubMed] | ||
− | == | + | =Chemotherapy & radiation therapy= |
+ | ==Carboplatin (Paraplatin), Paclitaxel (Taxol), concurrent RT== | ||
===Regimen=== | ===Regimen=== | ||
+ | ''Note: This regimen is listed by the NCCN, Non-Small Cell Lung Cancer version 2.2012, but this differs from the Belani, et al. 2005 reference, in which additional consolidation chemotherapy is given after completion of concurrent chemotherapy & radiation therapy. That [[#Carboplatin_.28Paraplatin.29.2C_Paclitaxel_.28Taxol.29.2C_concurrent_RT_-.3E_consolidation_chemo|regimen is detailed here]]. | ||
+ | |||
*[[Carboplatin (Paraplatin)]] AUC 2 IV over 30 minutes days 1, 8, 15 (administered second) | *[[Carboplatin (Paraplatin)]] AUC 2 IV over 30 minutes days 1, 8, 15 (administered second) | ||
*[[Paclitaxel (Taxol)]] 45 mg/m2 IV over 1 hour day 1, 8, 15 (administered first) | *[[Paclitaxel (Taxol)]] 45 mg/m2 IV over 1 hour day 1, 8, 15 (administered first) | ||
Line 127: | Line 107: | ||
:*2 Gy daily, 5 days per week; 9 additional fractions with an extra 18 Gy given for a total of 63 Gy over a total 7 week course of treatment | :*2 Gy daily, 5 days per week; 9 additional fractions with an extra 18 Gy given for a total of 63 Gy over a total 7 week course of treatment | ||
− | '''21-day cycles x 2 cycles''' | + | '''21-day cycles x 2 cycles''' |
===References=== | ===References=== | ||
# Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 1;23(25):5883-91. [http://jco.ascopubs.org/content/23/25/5883.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16087941 PubMed] | # Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 1;23(25):5883-91. [http://jco.ascopubs.org/content/23/25/5883.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16087941 PubMed] | ||
− | == | + | ==Carboplatin (Paraplatin), Paclitaxel (Taxol), concurrent RT -> consolidation chemo== |
===Regimen=== | ===Regimen=== | ||
− | *[[ | + | *[[Carboplatin (Paraplatin)]] AUC 2 IV over 30 minutes days 1, 8, 15 (administered second) |
− | *[[ | + | *[[Paclitaxel (Taxol)]] 45 mg/m2 IV over 1 hour day 1, 8, 15 (administered first) |
− | * | + | *Concurrent radiation therapy given: |
+ | :*1.8 Gy daily, 5 days per week; 25 fractions given over 5 weeks with 45 Gy overall dose, then | ||
+ | :*2 Gy daily, 5 days per week; 9 additional fractions with an extra 18 Gy given for a total of 63 Gy over a total 7 week course of treatment | ||
+ | |||
+ | '''21-day cycles x 2 cycles, THEN''' | ||
+ | |||
+ | *[[Carboplatin (Paraplatin)]] AUC 6 IV over 30 minutes day 1 (administered second) | ||
+ | *[[Paclitaxel (Taxol)]] 200 mg/m2 IV over 3 hours day 1 (administered first) | ||
− | ''' | + | '''21-day cycles x 2 cycles''' |
===References=== | ===References=== | ||
− | # | + | # Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 1;23(25):5883-91. [http://jco.ascopubs.org/content/23/25/5883.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16087941 PubMed] |
− | == | + | ==Carboplatin (Paraplatin), Paclitaxel (Taxol), sequential RT== |
===Regimen=== | ===Regimen=== | ||
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 30 minutes day 1 (administered second) | *[[Carboplatin (Paraplatin)]] AUC 6 IV over 30 minutes day 1 (administered second) | ||
Line 157: | Line 144: | ||
# Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 1;23(25):5883-91. [http://jco.ascopubs.org/content/23/25/5883.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16087941 PubMed] | # Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 1;23(25):5883-91. [http://jco.ascopubs.org/content/23/25/5883.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16087941 PubMed] | ||
− | == | + | ==Cisplatin (Platinol), Etoposide (Vepesid), concurrent RT== |
===Regimen=== | ===Regimen=== | ||
+ | *[[Cisplatin (Platinol)]] 50 mg/m2 IV on days 1, 8, 29, 36 | ||
+ | *[[Etoposide (Vepesid)]] 50 mg/m2 IV on days 1-5, 29-33 | ||
+ | *Concurrent radiation therapy (start within 24 hours of chemotherapy, 1.8 Gy per day, 5 days per week; 25 fractions given over 5 weeks total for a total of 45 Gy) | ||
+ | |||
+ | '''5-week initial course of chemotherapy & radiation, THEN''' | ||
+ | |||
+ | *Patients reimaged with CT scan (bone scan and head imaging were only done if patients had new symptoms), and those without progression or new metastatic disease received an additional 2 Gy per day x 8 fractions for a total of 61 Gy administered overall | ||
+ | |||
+ | ===References=== | ||
+ | # Albain KS, Crowley JJ, Turrisi AT 3rd, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002 Aug 15;20(16):3454-60. [http://jco.ascopubs.org/content/20/16/3454.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12177106 PubMed] | ||
+ | |||
+ | ==Cisplatin (Platinol), Etoposide (Vepesid), concurrent RT -> consolidation chemo== | ||
+ | ===Regimen=== | ||
+ | ''Note: The NCCN, Non-Small Cell Lung Cancer version 2.2012, describes "two extra cycles" of chemotherapy being given after completion of concurrent RT, but no primary reference can be found for this. It is unclear what the length of each cycle is supposed to be.'' | ||
*[[Cisplatin (Platinol)]] 50 mg/m2 IV on days 1, 8, 29, 36 | *[[Cisplatin (Platinol)]] 50 mg/m2 IV on days 1, 8, 29, 36 | ||
*[[Etoposide (Vepesid)]] 50 mg/m2 IV on days 1-5, 29-33 | *[[Etoposide (Vepesid)]] 50 mg/m2 IV on days 1-5, 29-33 | ||
Line 171: | Line 172: | ||
*[[Etoposide (Vepesid)]] 50 mg/m2 IV on days 1-5 | *[[Etoposide (Vepesid)]] 50 mg/m2 IV on days 1-5 | ||
− | '''28-day cycles x 2 cycles''' | + | '''28-day cycles x 2 cycles''' |
===References=== | ===References=== | ||
− | # Albain KS, Crowley JJ, Turrisi AT 3rd, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002 Aug 15;20(16):3454-60. [http://jco.ascopubs.org/content/20/16/3454.long link to original article] '''contains protocol | + | # Albain KS, Crowley JJ, Turrisi AT 3rd, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002 Aug 15;20(16):3454-60. [http://jco.ascopubs.org/content/20/16/3454.long link to original article] '''contains protocol'''--see note above [http://www.ncbi.nlm.nih.gov/pubmed/12177106 PubMed] |
− | == | + | ==Cisplatin (Platinol), Vinblastine (Velban), concurrent RT== |
===Regimen=== | ===Regimen=== | ||
− | *[[ | + | *[[Cisplatin (Platinol)]] 100 mg/m2 IV on days 1 & 29 |
− | *[[ | + | *[[Vinblastine (Velban)]] 5 mg/m2 IV on days 1, 8, 15, 22, 29 |
− | *Concurrent radiation therapy | + | *Concurrent radiation therapy |
− | |||
− | |||
− | ''' | + | '''5-week total course of chemotherapy''' |
− | |||
− | |||
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
− | # | + | # Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60. Epub 2011 Sep 8. [http://jnci.oxfordjournals.org/content/103/19/1452.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/21903745 PubMed] |
− | + | ==Cisplatin (Platinol), Vinblastine (Velban), sequential RT== | |
− | ==Cisplatin (Platinol) | ||
===Regimen=== | ===Regimen=== | ||
− | *[[ | + | *[[Cisplatin (Platinol)]] 100 mg/m2 IV on days 1 & 29 |
− | *[[ | + | *[[Vinblastine (Velban)]] 5 mg/m2 IV on days 1, 8, 15, 22, 29 |
+ | *Radiation therapy given after chemotherapy is complete | ||
− | ''' | + | '''5-week total course of chemotherapy''' |
===References=== | ===References=== | ||
− | # | + | # Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60. Epub 2011 Sep 8. [http://jnci.oxfordjournals.org/content/103/19/1452.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/21903745 PubMed] |
− | == | + | =Advanced or metastatic disease= |
+ | ==Carboplatin (Paraplatin) & Docetaxel (Taxotere)== | ||
===Regimen=== | ===Regimen=== | ||
− | *[[ | + | *[[Carboplatin (Paraplatin)]] AUC 6 IV day 1 |
*[[Docetaxel (Taxotere)]] 75 mg/m2 IV day 1 | *[[Docetaxel (Taxotere)]] 75 mg/m2 IV day 1 | ||
Line 213: | Line 208: | ||
===References=== | ===References=== | ||
− | # | + | # Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003 Aug 15;21(16):3016-24. Epub 2003 Jul 1. [http://jco.ascopubs.org/content/21/16/3016.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12837811 PubMed] |
− | == | + | ==Carboplatin (Paraplatin) & Gemcitabine (Gemzar)== |
===Regimen=== | ===Regimen=== | ||
− | *[[ | + | *[[Carboplatin (Paraplatin)]] AUC 5 IV day 1 |
− | *[[ | + | *[[Gemcitabine (Gemzar)]] 1000-1250 mg/m2 IV days 1 & 8 |
− | |||
− | |||
'''21-day cycles''' | '''21-day cycles''' | ||
===References=== | ===References=== | ||
− | # | + | # Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R, Gawande SR. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005 Nov 20;23(33):8380-8. [http://jco.ascopubs.org/content/23/33/8380.full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16293868 PubMed] |
− | + | # Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11. [http://jco.ascopubs.org/content/27/19/3217.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19433683 PubMed] | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Carboplatin (Paraplatin) & Paclitaxel (Taxol)== | ==Carboplatin (Paraplatin) & Paclitaxel (Taxol)== | ||
Line 259: | Line 243: | ||
# Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH; Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 1;26(1):60-5. [http://jco.ascopubs.org/content/26/1/60.full link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/18165641 PubMed] | # Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH; Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 1;26(1):60-5. [http://jco.ascopubs.org/content/26/1/60.full link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/18165641 PubMed] | ||
− | ==Carboplatin (Paraplatin) & | + | ==Carboplatin (Paraplatin) & Pemetrexed (Alimta)== |
===Regimen=== | ===Regimen=== | ||
*[[Carboplatin (Paraplatin)]] AUC 6 IV day 1 | *[[Carboplatin (Paraplatin)]] AUC 6 IV day 1 | ||
+ | *[[Pemetrexed (Alimta)]] 500 mg/m2 IV day 1 | ||
+ | *Cyanocobalamin (vitamin B12) 1000mcg IM every 9 weeks, first dose prior to pemetrexed | ||
+ | *Folic acid 1mg PO daily | ||
+ | |||
+ | '''21-day cycles''' | ||
+ | |||
+ | *[[Example orders for Carboplatin (Paraplatin) and Pemetrexed (Alimta) in non-small cell lung cancer]] | ||
+ | |||
+ | ===References=== | ||
+ | # Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11. [http://jco.ascopubs.org/content/27/19/3217.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19433683 PubMed] | ||
+ | |||
+ | ==Cisplatin (Platinol) & Docetaxel (Taxotere)== | ||
+ | ===Regimen=== | ||
+ | *[[Cisplatin (Platinol)]] 75 mg/m2 IV day 1 | ||
*[[Docetaxel (Taxotere)]] 75 mg/m2 IV day 1 | *[[Docetaxel (Taxotere)]] 75 mg/m2 IV day 1 | ||
Line 267: | Line 265: | ||
===References=== | ===References=== | ||
− | # | + | # Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8. [http://www.nejm.org/doi/full/10.1056/NEJMoa011954 link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11784875 PubMed] |
+ | |||
+ | ==Cisplatin (Platinol) & Gemcitabine (Gemzar)== | ||
+ | ===Regimen=== | ||
+ | *[[Cisplatin (Platinol)]] 100 mg/m2 IV day 1 | ||
+ | *[[Gemcitabine (Gemzar)]] 1000 mg/m2 IV days 1, 8, 15 | ||
+ | |||
+ | '''28-day cycles''' | ||
+ | |||
+ | ===References=== | ||
+ | # Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8. [http://www.nejm.org/doi/full/10.1056/NEJMoa011954 link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11784875 PubMed] | ||
− | == | + | ==Cisplatin (Platinol) & Paclitaxel (Taxol)== |
===Regimen=== | ===Regimen=== | ||
− | *[[ | + | *[[Paclitaxel (Taxol)]] 135 mg/m2 IV over 24 hours day 1 |
− | *[[ | + | *[[Cisplatin (Platinol)]] 75 mg/m2 IV day 2 |
− | |||
− | |||
'''21-day cycles''' | '''21-day cycles''' | ||
===References=== | ===References=== | ||
− | # | + | # Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8. [http://www.nejm.org/doi/full/10.1056/NEJMoa011954 link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11784875 PubMed] |
− | == | + | ==Cisplatin (Platinol) & Pemetrexed (Alimta)== |
===Regimen=== | ===Regimen=== | ||
− | *[[ | + | *[[Cisplatin (Platinol)]] 75 mg/m2 IV day 1 |
− | *[[ | + | *[[Pemetrexed (Alimta)]] 500 mg/m2 IV day 1 |
+ | *Cyanocobalamin (vitamin B12) 1000mcg IM every 9 weeks, first dose prior to pemetrexed | ||
+ | *Folic acid 1mg PO daily | ||
'''21-day cycles''' | '''21-day cycles''' | ||
===References=== | ===References=== | ||
− | # | + | # Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51. Epub 2008 May 27. [http://jco.ascopubs.org/content/26/21/3543.full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18506025 PubMed] |
− | |||
==Docetaxel (Taxotere)== | ==Docetaxel (Taxotere)== | ||
Line 297: | Line 304: | ||
'''21-day cycles''' | '''21-day cycles''' | ||
+ | |||
+ | *[[Example orders for Docetaxel (Taxotere) in non-small cell lung cancer]] | ||
Alternate schedule: | Alternate schedule: | ||
Line 306: | Line 315: | ||
# Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 1;22(9):1589-97. [http://jco.ascopubs.org/content/22/9/1589.full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/15117980 PubMed] | # Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 1;22(9):1589-97. [http://jco.ascopubs.org/content/22/9/1589.full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/15117980 PubMed] | ||
# Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest. 2006 Apr;129(4):1031-8. [http://chestjournal.chestpubs.org/content/129/4/1031.full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16608954 PubMed] | # Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest. 2006 Apr;129(4):1031-8. [http://chestjournal.chestpubs.org/content/129/4/1031.full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16608954 PubMed] | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Erlotinib (Tarceva)== | ==Erlotinib (Tarceva)== | ||
Line 330: | Line 328: | ||
===References=== | ===References=== | ||
# Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008 Nov 22;372(9652):1809-18. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61758-4/fulltext link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19027483 PubMed] | # Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008 Nov 22;372(9652):1809-18. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61758-4/fulltext link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19027483 PubMed] | ||
+ | |||
+ | ==Pemetrexed (Alimta)== | ||
+ | ===Regimen=== | ||
+ | *[[Pemetrexed (Alimta)]] 500 mg/m2 IV day 1 | ||
+ | *Cyanocobalamin (vitamin B12) 1000mcg IM every 9 weeks, first dose prior to pemetrexed | ||
+ | *Folic acid 1mg PO daily | ||
+ | |||
+ | '''21-day cycles''' | ||
+ | |||
+ | *[[Example orders for Pemetrexed (Alimta) in non-small cell lung cancer]] | ||
+ | |||
+ | ===References=== | ||
+ | # Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 1;22(9):1589-97. [http://jco.ascopubs.org/content/22/9/1589.full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/15117980 PubMed] |
Revision as of 02:43, 19 May 2012
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Adjuvant therapy
Carboplatin (Paraplatin) & Paclitaxel (Taxol)
Regimen
- Carboplatin (Paraplatin) AUC 6 IV over 45-60 minutes day 1
- Paclitaxel (Taxol) 200 mg/m2 IV over 3 hours day 1
21-day cycles x 4 cycles
References
- Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 1;26(31):5043-51. Epub 2008 Sep 22. link to original article contains protocol PubMed
Cisplatin (Platinol) & Docetaxel (Taxotere)
Regimen
- Cisplatin (Platinol) 75 mg/m2 IV day 1
- Docetaxel (Taxotere) 75 mg/m2 IV day 1
21-day cycles x 4 cycles
References
- Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003 Aug 15;21(16):3016-24. Epub 2003 Jul 1. link to original article contains protocol PubMed
Cisplatin (Platinol) & Etoposide (Vepesid)
Regimen
- Cisplatin (Platinol) 100 mg/m2 IV on day 1
- Etoposide (Vepesid) 100 mg/m2 IV on days 1-3
28-day cycles x 4 cycles
References
- Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60. link to original article PubMed
Cisplatin (Platinol) & Gemcitabine (Gemzar)
Regimen
- Cisplatin (Platinol) 75 mg/m2 IV on day 1
- Gemcitabine (Gemzar) 1250 mg/m2 IV on days 1, 8
21-day cycles x 4 cycles
References
- Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51. Epub 2008 May 27. link to original article contains protocol PubMed
Cisplatin (Platinol) & Pemetrexed (Alimta)
Regimen
- Cisplatin (Platinol) 75 mg/m2 IV day 1
- Pemetrexed (Alimta) 500 mg/m2 IV day 1
21-day cycles x 4 cycles
References
- Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51. Epub 2008 May 27. link to original article contains protocol; note: reference was not for adjuvant therapy; patients in this study were stage IIIB or IV PubMed
Cisplatin (Platinol) & Vinblastine (Velban)
Regimen
- Cisplatin (Platinol) 80 mg/m2 IV on day 1
- Vinblastine (Velban) 4 mg/m2 IV on days 1, 8, 15 of cycle 1
- Vinblastine (Velban) 4 mg/m2 IV on days 1 & 8 of cycle 2
- Vinblastine (Velban) 4 mg/m2 IV on days 1 & 15 of cycle 3
- Vinblastine (Velban) 4 mg/m2 IV on day 8 of cycle 4
- Note: The above vinblastine schedule is based on it being given as described every 2 weeks after cycle 2 day 8
21-day cycles x 4 cycles
References
- Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60. link to original article PubMed
Regimen #1, Winton, et al. 2005
- Cisplatin (Platinol) 50 mg/m2 IV on days 1 & 8
- Vinorelbine (Navelbine) 25 mg/m2 IV on days 1, 8, 15, 22
28-day cycles x 4 cycles
Regimen #2, Hotta, et al. 2001
- Cisplatin (Platinol) 75-80 mg/m2 IV on day 1
- Vinorelbine (Navelbine) 25-30 mg/m2 IV on days 1, 8
21-day cycles x 4 cycles
Regimen #3, Arriagada, et al. 2004 & Douillard, et al. 2006
- Cisplatin (Platinol) 100 mg/m2 IV on day 1
- Vinorelbine (Navelbine) 30 mg/m2 IV on days 1, 8, 15, 22
28-day cycles x 4 cycles
References
- Hotta K, Sekine I, Tamura T, Sawada M, Watanabe H, Kusaba H, Akiyama Y, Inoue A, Shimoyama T, Nokihara H, Ueda Y, Yamamoto N, Kunitoh H, Ohe Y, Kodama T, Saijo N. A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol. 2001 Dec;31(12):596-600. link to original article contains protocol PubMed
- Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60. link to original article PubMed content property of HemOnc.org
- Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23;352(25):2589-97. link to original article PubMed
- Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006 Sep;7(9):719-27. link to original article PubMed
Chemotherapy & radiation therapy
Carboplatin (Paraplatin), Paclitaxel (Taxol), concurrent RT
Regimen
Note: This regimen is listed by the NCCN, Non-Small Cell Lung Cancer version 2.2012, but this differs from the Belani, et al. 2005 reference, in which additional consolidation chemotherapy is given after completion of concurrent chemotherapy & radiation therapy. That regimen is detailed here.
- Carboplatin (Paraplatin) AUC 2 IV over 30 minutes days 1, 8, 15 (administered second)
- Paclitaxel (Taxol) 45 mg/m2 IV over 1 hour day 1, 8, 15 (administered first)
- Concurrent radiation therapy given:
- 1.8 Gy daily, 5 days per week; 25 fractions given over 5 weeks with 45 Gy overall dose, then
- 2 Gy daily, 5 days per week; 9 additional fractions with an extra 18 Gy given for a total of 63 Gy over a total 7 week course of treatment
21-day cycles x 2 cycles
References
- Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 1;23(25):5883-91. link to original article contains protocol PubMed
Carboplatin (Paraplatin), Paclitaxel (Taxol), concurrent RT -> consolidation chemo
Regimen
- Carboplatin (Paraplatin) AUC 2 IV over 30 minutes days 1, 8, 15 (administered second)
- Paclitaxel (Taxol) 45 mg/m2 IV over 1 hour day 1, 8, 15 (administered first)
- Concurrent radiation therapy given:
- 1.8 Gy daily, 5 days per week; 25 fractions given over 5 weeks with 45 Gy overall dose, then
- 2 Gy daily, 5 days per week; 9 additional fractions with an extra 18 Gy given for a total of 63 Gy over a total 7 week course of treatment
21-day cycles x 2 cycles, THEN
- Carboplatin (Paraplatin) AUC 6 IV over 30 minutes day 1 (administered second)
- Paclitaxel (Taxol) 200 mg/m2 IV over 3 hours day 1 (administered first)
21-day cycles x 2 cycles
References
- Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 1;23(25):5883-91. link to original article contains protocol PubMed
Carboplatin (Paraplatin), Paclitaxel (Taxol), sequential RT
Regimen
- Carboplatin (Paraplatin) AUC 6 IV over 30 minutes day 1 (administered second)
- Paclitaxel (Taxol) 200 mg/m2 IV over 3 hours day 1 (administered first)
21-day cycles x 2 cycles
- Radiation therapy given after chemotherapy is complete:
- 1.8 Gy daily, 5 days per week; 25 fractions given over 5 weeks with 45 Gy overall dose, then
- 2 Gy daily, 5 days per week; 9 additional fractions with an extra 18 Gy given for a total of 63 Gy over a total 7 week course of treatment
References
- Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 1;23(25):5883-91. link to original article contains protocol PubMed
Cisplatin (Platinol), Etoposide (Vepesid), concurrent RT
Regimen
- Cisplatin (Platinol) 50 mg/m2 IV on days 1, 8, 29, 36
- Etoposide (Vepesid) 50 mg/m2 IV on days 1-5, 29-33
- Concurrent radiation therapy (start within 24 hours of chemotherapy, 1.8 Gy per day, 5 days per week; 25 fractions given over 5 weeks total for a total of 45 Gy)
5-week initial course of chemotherapy & radiation, THEN
- Patients reimaged with CT scan (bone scan and head imaging were only done if patients had new symptoms), and those without progression or new metastatic disease received an additional 2 Gy per day x 8 fractions for a total of 61 Gy administered overall
References
- Albain KS, Crowley JJ, Turrisi AT 3rd, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002 Aug 15;20(16):3454-60. link to original article contains protocol PubMed
Cisplatin (Platinol), Etoposide (Vepesid), concurrent RT -> consolidation chemo
Regimen
Note: The NCCN, Non-Small Cell Lung Cancer version 2.2012, describes "two extra cycles" of chemotherapy being given after completion of concurrent RT, but no primary reference can be found for this. It is unclear what the length of each cycle is supposed to be.
- Cisplatin (Platinol) 50 mg/m2 IV on days 1, 8, 29, 36
- Etoposide (Vepesid) 50 mg/m2 IV on days 1-5, 29-33
- Concurrent radiation therapy (start within 24 hours of chemotherapy, 1.8 Gy per day, 5 days per week; 25 fractions given over 5 weeks total for a total of 45 Gy)
5-week initial course of chemotherapy & radiation, THEN
- Patients reimaged with CT scan (bone scan and head imaging were only done if patients had new symptoms), and those without progression or new metastatic disease received an additional 2 Gy per day x 8 fractions for a total of 61 Gy administered overall
Additional chemotherapy:
- Cisplatin (Platinol) 50 mg/m2 IV on days 1 & 8
- Etoposide (Vepesid) 50 mg/m2 IV on days 1-5
28-day cycles x 2 cycles
References
- Albain KS, Crowley JJ, Turrisi AT 3rd, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002 Aug 15;20(16):3454-60. link to original article contains protocol--see note above PubMed
Cisplatin (Platinol), Vinblastine (Velban), concurrent RT
Regimen
- Cisplatin (Platinol) 100 mg/m2 IV on days 1 & 29
- Vinblastine (Velban) 5 mg/m2 IV on days 1, 8, 15, 22, 29
- Concurrent radiation therapy
5-week total course of chemotherapy
References
- Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60. Epub 2011 Sep 8. link to original article PubMed
Cisplatin (Platinol), Vinblastine (Velban), sequential RT
Regimen
- Cisplatin (Platinol) 100 mg/m2 IV on days 1 & 29
- Vinblastine (Velban) 5 mg/m2 IV on days 1, 8, 15, 22, 29
- Radiation therapy given after chemotherapy is complete
5-week total course of chemotherapy
References
- Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60. Epub 2011 Sep 8. link to original article PubMed
Advanced or metastatic disease
Carboplatin (Paraplatin) & Docetaxel (Taxotere)
Regimen
- Carboplatin (Paraplatin) AUC 6 IV day 1
- Docetaxel (Taxotere) 75 mg/m2 IV day 1
21-day cycles
References
- Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003 Aug 15;21(16):3016-24. Epub 2003 Jul 1. link to original article contains protocol PubMed
Carboplatin (Paraplatin) & Gemcitabine (Gemzar)
Regimen
- Carboplatin (Paraplatin) AUC 5 IV day 1
- Gemcitabine (Gemzar) 1000-1250 mg/m2 IV days 1 & 8
21-day cycles
References
- Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R, Gawande SR. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005 Nov 20;23(33):8380-8. link to original article contains protocol PubMed
- Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11. link to original article contains protocol PubMed
Carboplatin (Paraplatin) & Paclitaxel (Taxol)
Regimen
- Carboplatin (Paraplatin) AUC 6 IV day 1 (administer second)
- Paclitaxel (Taxol) 200-225 mg/m2 IV over 3 hours on day 1 (administer first)
21-day cycles
References
- Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8. link to original article contains protocol PubMed
Carboplatin (Paraplatin), Paclitaxel (Taxol), Bevacizumab (Avastin)
Regimen
- Carboplatin (Paraplatin) AUC 6 IV day 1 (administer second)
- Paclitaxel (Taxol) 200-225 mg/m2 IV over 3 hours on day 1 (administer first)
- Bevacizumab (Avastin) 15 mg/kg IV day 1
21-day cycles
References
- Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 Jun 1;22(11):2184-91. link to original article PubMed
- Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH; Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 1;26(1):60-5. link to original article PubMed
Carboplatin (Paraplatin) & Pemetrexed (Alimta)
Regimen
- Carboplatin (Paraplatin) AUC 6 IV day 1
- Pemetrexed (Alimta) 500 mg/m2 IV day 1
- Cyanocobalamin (vitamin B12) 1000mcg IM every 9 weeks, first dose prior to pemetrexed
- Folic acid 1mg PO daily
21-day cycles
References
- Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11. link to original article contains protocol PubMed
Cisplatin (Platinol) & Docetaxel (Taxotere)
Regimen
- Cisplatin (Platinol) 75 mg/m2 IV day 1
- Docetaxel (Taxotere) 75 mg/m2 IV day 1
21-day cycles
References
- Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8. link to original article contains protocol PubMed
Cisplatin (Platinol) & Gemcitabine (Gemzar)
Regimen
- Cisplatin (Platinol) 100 mg/m2 IV day 1
- Gemcitabine (Gemzar) 1000 mg/m2 IV days 1, 8, 15
28-day cycles
References
- Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8. link to original article contains protocol PubMed
Cisplatin (Platinol) & Paclitaxel (Taxol)
Regimen
- Paclitaxel (Taxol) 135 mg/m2 IV over 24 hours day 1
- Cisplatin (Platinol) 75 mg/m2 IV day 2
21-day cycles
References
- Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8. link to original article contains protocol PubMed
Cisplatin (Platinol) & Pemetrexed (Alimta)
Regimen
- Cisplatin (Platinol) 75 mg/m2 IV day 1
- Pemetrexed (Alimta) 500 mg/m2 IV day 1
- Cyanocobalamin (vitamin B12) 1000mcg IM every 9 weeks, first dose prior to pemetrexed
- Folic acid 1mg PO daily
21-day cycles
References
- Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51. Epub 2008 May 27. link to original article contains protocol PubMed
Docetaxel (Taxotere)
Regimen
- Docetaxel (Taxotere) 75 mg/m2 IV day 1
21-day cycles
Alternate schedule:
- Docetaxel (Taxotere) 35 mg/m2 IV days 1, 8, 15
28-day cycles
References
- Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 1;22(9):1589-97. link to original article contains protocol PubMed
- Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest. 2006 Apr;129(4):1031-8. link to original article contains protocol PubMed
Erlotinib (Tarceva)
- Erlotinib (Tarceva) 150 mg PO daily
References
- Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, Witt K, Botkin D. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol. 2008 Feb 20;26(6):863-9. link to original article contains protocol PubMed
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32. link to original article contains protocol PubMed
Gefitinib (Iressa)
- Gefitinib (Iressa) 250 mg PO daily
References
- Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008 Nov 22;372(9652):1809-18. link to original article contains protocol PubMed
Pemetrexed (Alimta)
Regimen
- Pemetrexed (Alimta) 500 mg/m2 IV day 1
- Cyanocobalamin (vitamin B12) 1000mcg IM every 9 weeks, first dose prior to pemetrexed
- Folic acid 1mg PO daily
21-day cycles
References
- Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 1;22(9):1589-97. link to original article contains protocol PubMed